Epsilogen appoints Ashley Nagle as CBO

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, has appointed Ashley Nagle as chief business officer (CBO) with immediate effect as part of a broader company expansion.

Mr Nagle brings over 25 years of experience leading business and strategy development, licensing and deal-making within the biopharmaceutical industry. Most recently, he served as vice president of business development at RemedyBio, a discovery and development precision immunotherapy company. During his career Mr Nagle has worked with both small and large organizations, including Lonza Biologics, Almac Sciences, Fulcrum Pharma, OncoSynergy, NexGenix and SeaGull Therapeutics, where he was chief executive.

Mr Nagle’s appointment comes amidst a broader company expansion that will enable Epsilogen to unlock the potential of both IgE antibodies and their engineered derivatives as an entirely new treatment modality for patients with cancer.